Venaxis secuers European commercial development agreements for APPY1 Venaxis announced it has executed two additional commercial development agreements as part of the initial phase of the European launch. MOSS S.p.A. of Italy and SAVAS Medikal Inc. of Turkey have committed to market development activities within their respective territories and each have submitted initial stocking purchase orders for the APPY1 test/system. Venaxis announced a similar agreement with EMELCA Bioscience earlier this year that covers Belgium, Luxembourg, and the Netherlands.
News For APPY From The Last 14 Days
Check below for free stories on APPY the last two weeks.
Subscribe for More Information